Catalent Inc. (CTLT)
NYSE: CTLT
· Real-Time Price · USD
63.48
0.00 (0.00%)
At close: Dec 17, 2024, 10:00 PM
Catalent Revenue Breakdown
| Period Ending | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|
| Biologics Revenue | 1.95B | 1.98B | 2.55B | 1.93B | 1.02B | 742.1M | 601.9M |
| Biologics Revenue Growth | -1.31% | -22.40% | +32.21% | +88.72% | +37.66% | +23.29% | n/a |
| PharmaConsumerHealth Revenue | 2.43B | 2.29B | n/a | n/a | n/a | n/a | n/a |
| PharmaConsumerHealth Revenue Growth | +6.30% | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2024 | Jun 30, 2023 | Jun 29, 2022 | Jun 29, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 1.36B | 1.26B | 1.51B | 1.34B | 976.1M | 842.1M | 897.8M | 797.4M | 733.2M | 795.4M | 888.8M |
| Europe Revenue Growth | +8.11% | -16.53% | +12.14% | +37.59% | +15.91% | -6.20% | +12.59% | +8.76% | -7.82% | -10.51% | n/a |
| International Other Revenue | 356M | 355M | 327M | 288M | 375.8M | 433.8M | 415.3M | 345M | 313.5M | 268.6M | 278.8M |
| International Other Revenue Growth | +0.28% | +8.56% | +13.54% | -23.36% | -13.37% | +4.45% | +20.38% | +10.05% | +16.72% | -3.66% | n/a |
| North America Revenue | 2.82B | 2.77B | 3.08B | 2.46B | 1.82B | 1.32B | n/a | n/a | n/a | n/a | n/a |
| North America Revenue Growth | +1.99% | -10.25% | +25.26% | +35.11% | +38.33% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 252M | 218M | 214M | 180M | 215M | 219M | 190M | 226M | 196M | 226M | 207M | 228M | 183M | 184M | 172.7M | 165.5M | 164.7M | 158M | 136.1M | 141M | 142.8M | 143.4M | 129.9M | 123.2M | 115.5M | 124.3M | 117M | 114.3M | 107M | 107.3M | 100.9M | 96.2M | 98.2M | 89.5M | 93.2M | 93M | 82.2M | 86.9M | 80.9M |
| Selling, General, and Administrative Revenue Growth | +15.60% | +1.87% | +18.89% | -16.28% | -1.83% | +15.26% | -15.93% | +15.31% | -13.27% | +9.18% | -9.21% | +24.59% | -0.54% | +6.54% | +4.35% | +0.49% | +4.24% | +16.09% | -3.48% | -1.26% | -0.42% | +10.39% | +5.44% | +6.67% | -7.08% | +6.24% | +2.36% | +6.82% | -0.28% | +6.34% | +4.89% | -2.04% | +9.72% | -3.97% | +0.22% | +13.14% | -5.41% | +7.42% | n/a |
| Research and Development Revenue | n/a | 5M | 4M | 4M | 4M | 5M | 4M | 4M | 5M | 5M | 6M | 6M | 6M | 6M | 3.4M | 6M | 6M | 5.6M | 5.9M | 4.9M | 4.6M | 14.7M | 12.7M | 15.3M | 11.8M | 13.8M | 13M | 13.9M | 11.8M | 14.7M | 13.8M | 12.5M | 11.8M | 13.4M | 13.8M | 14.4M | 13.4M | 15.1M | 13.4M |
| Research and Development Revenue Growth | -100.00% | +25.00% | 0.00% | 0.00% | -20.00% | +25.00% | 0.00% | -20.00% | 0.00% | -16.67% | 0.00% | 0.00% | 0.00% | +76.47% | -43.33% | 0.00% | +7.14% | -5.08% | +20.41% | +6.52% | -68.71% | +15.75% | -16.99% | +29.66% | -14.49% | +6.15% | -6.47% | +17.80% | -19.73% | +6.52% | +10.40% | +5.93% | -11.94% | -2.90% | -4.17% | +7.46% | -11.26% | +12.69% | n/a |